<i>JAK2</i>V617F in idiopathic venous thromboembolism occurring in the absence of inherited or acquired thrombophilia

Rossi, Davide; Cresta, Stefania; Destro, Tamara Rodrigues da Silva; Vendramin, Chiara; Bocchetta, Simone; Paoli, Lorenzo De; Cerri, Michaela; Lunghi, Monia; Gaïdano, Gianluca

doi:10.1111/j.1365-2141.2007.06715.x

Cited by 17 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21,27,34,37,40,42,47 Eight of 248 patients with CVT had JAK2V617F mutation, for a mean prevalence of 2.57% (95% CI, 0.97%-4.91%). 21,24,40,41,45,51 One of 153 patients with RVO had JAK2V617F mutation, for a mean prevalence of 0.99% (95% CI, 0.05%-3.20%). 21,31,40,41,47,48 Discussion This is the first systematic review and meta-analysis that assessed the role of JAK2 mutation in patients with venous thrombosis.…”

Section: Patients With Vte In Other Sitesmentioning

confidence: 99%

“…21,24,40,41,45,51 One of 153 patients with RVO had JAK2V617F mutation, for a mean prevalence of 0.99% (95% CI, 0.05%-3.20%). 21,31,40,41,47,48 Discussion This is the first systematic review and meta-analysis that assessed the role of JAK2 mutation in patients with venous thrombosis. The results of this study indicate that the prevalence of this mutation is high in patients with SVT.…”

Section: Patients With Vte In Other Sitesmentioning

confidence: 99%

“…Twenty-four studies were therefore included in this systematic review. 10,21,23,25,27,30,33,37,[40][41][42][43][44][45][46][47][48][49]51,52 Interobserver agreement for study selection was excellent ( ϭ 0.96).…”

Section: Study Identification and Selectionmentioning

confidence: 99%

“…Studies ranged in size from 11 to 560 patients; a total of 3508 patients were included. Six case-control studies 10,23,25,27,35,40 and 18 retrospective cohort studies 21,24,30,31,34,36,37,[41][42][43][44][45][46][47][48][49]51,52 were included in our systematic review. Five studies enrolled patients consecutively.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…[24][25][26][27][28][29][30][31][32][33][34][35] Sixteen studies, 10,21,[23][24][25]30,[35][36][37]40,43,44,46,47,49,53 including a total 831 patients, assessed the prevalence of JAK2V617F mutation in patients with SVT. Eight studies, 21,27,34,37,[40][41][42]47 …”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

JAK2V617F mutation for the early diagnosis of Ph− myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis

Dentali

Squizzato

Brivio

et al. 2009

Blood

158

136

View full text Add to dashboard Cite

Recent studies suggested that JAK2V617F mutation is frequent in patients with splanchnic vein thrombosis (SVT) but not in patients with other venous thromboembolic events (VTE). However, whether screening for the JAK2V617F mutation in VTE patients is justified remains unclear. Therefore, we performed a systematic review to assess the frequency of JAK2 mutation in VTE patients and the role of JAK2V617F mutation in the diagnosis of myeloproliferative neoplasms. MEDLINE and EMBASE databases were searched. Two reviewers independently performed study selection and extracted study characteristics. Pooled odds ratios of case-control studies and weighted mean proportion of the prevalence of JAK2V617F mutation of uncontrolled series were calculated. Twenty-four studies involving 3123 patients were included. Mean prevalence of JAK2 mutation was 32.7% (95% confidence interval, 25.5%-35.9%) in SVT patients. JAK2 mutation was associated with increased risk of SVT (odds ratio, 53.98; 95% confidence interval, 13.10-222.45). Mean prevalence of JAK2 mutation in other VTE patients was low (range, 0.88%-2.57%). Presence of JAK2V617F mutation in SVT patients was associated with a subsequent diagnosis of myeloproliferative neoplasm in many patients. JAK2 mutation is strongly associated with SVT, and routine screening of JAK2 mutation appears to be indicated in these patients. (Blood. 2009;113:5617-5623)

show abstract